Brazil Approves First Generic Ozempic, With EMS Pricing Ozivy 30% Below Novo Nordisk’s Shot
Updated
Updated · STAT · May 27
Brazil Approves First Generic Ozempic, With EMS Pricing Ozivy 30% Below Novo Nordisk’s Shot
5 articles · Updated · STAT · May 27
EMS won clearance to sell Ozivy, Brazil’s first generic version of Ozempic, for adults with type 2 diabetes alongside diet and exercise.
30% lower pricing than Ozempic is expected to open cheaper competition in one of the world’s fastest-growing markets for diabetes and weight-loss drugs.
350,000 pens will be available initially, with EMS targeting a launch within 30 days and about 1.2 million units sold in the first year.
The approval marks a milestone for Brazil’s drug industry as local manufacturers push into the booming GLP-1 market dominated by products such as Novo Nordisk’s Ozempic.
With Brazil’s generic Ozempic, how will the global weight-loss drug market change?
Why did Europe approve a cancer drug that a US panel just rejected?